Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
Medical School Administrators Concerned About Insufficient Resources for Incoming Students
According to annual survey results published by the Association of American Medical Colleges (AAMC), medical school administrators are worried about a lack of training...
U.S. Officials Announce Plans for Coronavirus Vaccine
Federal officials announced on September 16 that they are planning to administer a free coronavirus vaccine to Americans within 24 hours of approval or...
FDA Releases Comparative Performance Data for COVID-19 Diagnostic Tests
To help labs, clinicians, and patients evaluate competing COVID-19 diagnostic screening products, the FDA has released performance data for more than 55 tests.
When diagnostic...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.